Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib

Aim: To assess real-world clinical outcomes in patients with non-small-cell lung cancer with MET exon 14 skipping mutation and brain metastases (BM) who received capmatinib, a recently approved MET inhibitor, in routine US clinical practice. 

Materials & methods: Patient data were collected using a retrospective medical record review, led by participating oncologists. Eligible patients initiated treatment with capmatinib in any line, after BM diagnosis, between May 2020 and June 2021. Data on real-world overall response rate (rwORR) and real-world progression-free survival (rwPFS) were descriptively analyzed. 

Results: 68 eligible patients were analyzed. In patients treated with first-line (1L) capmatinib (n = 55), the rwORR was 90.9% systemically and 87.3% intracranially; median systemic rwPFS was 14.1 months. Among radiation-naive patients on 1L capmatinib (n = 20), rwORR was 85.0%, both systemically and intracranially; median systemic rwPFS was 14.1 months. 

Conclusion: This study showed substantial systemic and intracranial effectiveness for capmatinib in real-world setting; findings were consistent for RT-naive patients.

Comments：

The study aimed to assess the real-world clinical outcomes of capmatinib, a MET inhibitor, in patients with non-small-cell lung cancer with MET exon 14 skipping mutation and brain metastases. The patient data were collected using a retrospective medical record review led by participating oncologists. The eligible patients received capmatinib in any line after brain metastasis diagnosis, between May 2020 and June 2021. The real-world overall response rate (rwORR) and real-world progression-free survival (rwPFS) were descriptively analyzed.

The study analyzed data from 68 eligible patients. In patients treated with first-line (1L) capmatinib (n = 55), the rwORR was 90.9% systemically and 87.3% intracranially, and the median systemic rwPFS was 14.1 months. Among radiation-naive patients on 1L capmatinib (n = 20), the rwORR was 85.0%, both systemically and intracranially, and the median systemic rwPFS was also 14.1 months.

The study's conclusion suggests that capmatinib is effective in a real-world setting for patients with non-small-cell lung cancer with MET exon 14 skipping mutation and brain metastases, with substantial systemic and intracranial effectiveness. These findings were consistent for radiation-naive patients.

Related Products

Cat.No.	Product Name	Information
S2788	Capmatinib	Capmatinib is a novel, ATP-competitive inhibitor of c-MET with IC50 of 0.13 nM in a cell-free assay, inactive against RONβ, as well as EGFR and HER-3. Capmatinib (INCB28060) inhibits Wnt/β-catenin and EMT signaling pathways and induces apoptosis in diffuse gastric cancer positive for c-MET amplification. Phase 1.

Related Targets

Apoptosis related Wnt/beta-catenin c-Met